Investigational drug · Phase 2
PF-07328948
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Heart Failure.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "PF-07328948"
First trial start
2025
Jun 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-07328948", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-07328948" as an intervention, largest first.
- A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06991257 · 620 participants (planned) · Start Jun 19, 2025 · Primary completion May 8, 2028
Drug: Placebo; Low Dose PF-07328948 and 2 more · For: Heart Failure
Sites: Beverly Hills, California; Lake Forest, California; Santa Maria, California · 150 sites in all
PfizerPfizer (PFE)
NCT05807490 · 86 participants · Start Apr 5, 2023 · Primary completion Jul 10, 2024
Drug: PF-07328948; Placebo and 20 more · For: Healthy
Sites: New Haven, Connecticut; Brussels, Belgium
PfizerPfizer (PFE)
NCT07315360 · 28 participants (planned) · Start Jan 28, 2026 · Primary completion Mar 13, 2027
Drug: PF-07328948 · For: Renal Impairment; Healthy
Sites: Lake Forest, California; Orlando, Florida; Tampa, Florida · 4 sites in all
PfizerPfizer (PFE)
NCT06837259 · 26 participants · Start Mar 19, 2025 · Primary completion Jun 11, 2025
Drug: PF-07328948; cyclosporine and 1 more · For: Healthy Adults
Sites: Brussels, Belgium
PfizerPfizer (PFE)
NCT07269301 · 26 participants (planned) · Start Dec 22, 2025 · Primary completion Feb 23, 2027
Drug: PF-07328948 · For: Hepatic Impairment; Healthy
Sites: Lake Forest, California; Orlando, Florida; Tampa, Florida
- A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult ParticipantsCompleted
PfizerPfizer (PFE)
NCT05654181 · 20 participants · Start Oct 17, 2022 · Primary completion May 3, 2023
Drug: PF-07328948; Placebo · For: Healthy
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07455240 · 10 participants · Start Mar 2, 2026 · Primary completion Apr 15, 2026
Drug: PF-07328948 · For: Healthy Participant
Sites: Beijing, China
PfizerPfizer (PFE)
NCT07508228 · 8 participants · Start Apr 3, 2026 · Primary completion Jul 10, 2026
Drug: Oral [14C]PF-07328948; Oral Unlabeled PF-07328948 and 1 more · For: Healthy
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- Clinically Advancing BDK Inhibitors.
Sreenivas K, Nageswara Rao C · J Med Chem 2025
- Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948.
Filipski KJ, Martinez-Alsina LA, Reese MR, et al. · J Med Chem 2025
Also in development for Heart Failure
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- HiCM-188 therapyPhase 32 trials
HELP Therapeutics Co., Ltd. · Heart Failure
- Qishen Yiqi Dripping Pills 2 bagsPhase 32 trials
Tasly Pharmaceutical Group Co., Ltd · Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.